- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00398892
The Effects of Lipoic Acid on Glycaemic Control in Type 2 Diabetes
Hypothesis: that lipoic acid supplements taken orally will improve control of blood sugar levels in people with type 2 diabetes.
This study will recruit 18 people with type 2 diabetes, whose diabetes is currently managed on oral agents. Each subject will then either take placebo for 12 weeks followed by lipoic acid for 12 weeks, or lipoic acid followed by placebo.
A blood test for overall diabetes control will be taken at the start and end of each 12 week period, and the change in control will be compared for lipoic acid vs placebo.
Study Overview
Detailed Description
This is a randomized, double-blinded, placebo-controlled crossover trial of lipoic acid for glycaemic control in type 2 diabetes.
The trial has 3 phases, each lasting 12 weeks. During phases 1 and 3, subjects take lipoic acid or placebo tablets, the order to be determined by randomization. Phase 2 is a 12-week washout period. The intervention is lipoic acid 200mg daily for 1 week, 400mg daily for the second week, and 600mg daily for weeks 3-12. Equivalent numbers of placebo tablets will be taken during the placebo phase.
The principal outcome measure is change in HbA1c between the start and end of lipoic acid supplementation, by comparison with the same change with placebo.
The secondary outcome measure is change in urine albumin:creatinine ratio over the same periods.
Assessments for safety will include standard adverse events reporting, repeated laboratory measurements throughout the study (blood count, renal and liver function) and hypoglycaemia frequency.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: James D Walker, MD
- Phone Number: +44 1506 419666
- Email: james.walker@wlt.scot.nhs.uk
Study Contact Backup
- Name: Roderick E Warren
- Phone Number: +44 131 537 1752
- Email: roderick.warren@luht.scot.nhs.uk
Study Locations
-
-
Scotland
-
Livingston, Scotland, United Kingdom, EH54 6PP
- Recruiting
- Diabetes Department, St John's Hospital
-
Principal Investigator:
- James D Walker, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetes
- Age > 18 years
- Capable of giving informed consent
- Treated with oral antidiabetic agents (not insulin)
- HbA1c 7.0 - 8.5% at last measurement (must be within 6 months of study)
- Most recent HbA1c within 1% of all measurements within preceding year
- Prepared to self-test blood glucose on a regular basis
- Prepared to use contraception during study if of child-bearing potential
Exclusion Criteria:
- Unstable cardiac disease (NYHA class III or IV heart failure, or unstable angina or myocardial infarction within last three months)
- Significant renal or hepatic impairment (creatinine>170 micromol/L, alanine transaminase or alkaline phosphatase > 3x upper limit of normal)
- Other medical condition or treatment likely to affect glycaemic control
- Previous history of significant hypoglycaemia
- Pregnancy
- Involvement in other clinical trial in last three months
- Known or suspected sensitivity to trial products
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 1
Crossover - placebo then active
|
Lipoic acid capsules
|
Other: 2
Crossover - active then placebo
|
Lipoic acid capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HbA1c change for lipoic acid vs placebo
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Urine ACR change for lipoic acid vs placebo
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: James D Walker, NHS Lothian - St John's Hospital, Livingston
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2005-001543-36
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
Clinical Trials on Lipoic acid
-
Rebecca SpainCompletedComparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple SclerosisProgressive Multiple Sclerosis | Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
InVasc Therapeutics, Inc.CompletedHypertension | DiabetesUnited States
-
Oregon Health and Science UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedMultiple SclerosisUnited States
-
Oregon Health and Science UniversityNational Institute on Aging (NIA); National Center for Research Resources (NCRR)CompletedInflammation | Dementia | Oxidative Stress | Hyperlipidemia | Alzheimer's DiseaseUnited States
-
Augusta UniversityXinjiang Medical UniversityCompletedObesity | Cardiovascular Disease | Type 2 DiabetesChina
-
Oregon Health and Science UniversityCompleted
-
Oregon State UniversityOregon Health and Science University; National Center for Complementary and...Active, not recruiting
-
University Health Network, TorontoCanadian Diabetes AssociationCompletedType 2 Diabetes | PrediabetesCanada
-
Khyber Medical University PeshawarActive, not recruitingPeripheral Diabetic NeuropathyPakistan